Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 6Prostatic Neoplasms 4Neuroblastoma 4Colorectal Neoplasms 4Ovarian Neoplasms 3Glioblastoma 3Breast Neoplasms 3Uveal Melanoma 2Neoplasms 2Breast Neoplasms, Male 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Multiple Myeloma 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Kidney Neoplasms 1Hematologic Neoplasms 1Graft vs Host Disease 1Glioma 1Ependymoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01784913 2024-12-16

UV1/hTERT2012P

Ultimovacs ASA

Phase 1/2 Completed
22 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00088413 2019-04-16

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
51 enrolled 20 charts
BreastGastrointestinalGynecologic

Adenocarcinoma, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡